Analyst Research Report Snapshot

Title:

AB SCIENCE - PANCREATIC POTENTIAL

Price:

$10.00

Provider:

Edison Investment Research

Date:

13 Feb 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ABS.PA

Available for Immediate Download
Summary:

Subset analysis data presented at ASCO-GI highlight the potential of masitinib in pancreatic cancer. In particular, the improvement in overall survival of six months in patients with a specific biomarker compares very favourably with other gemcitabine combinations. A decision on European conditional approval in both this and the GIST indication is due in Q4/13 and is likely to be a key value driver for the shares.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.